Laporkan Masalah

Efek Injeksi Intrakamera Moxifloxacin Tanpa Pengawet Dibandingkan dengan Injeksi Intrakamera Levofloxacin Tanpa Pengawet: Pengamatan Kadar MCP-1 Air Mata dan Kondisi Klinis Sesudah Fakoemulsifikasi pada Pasien Katarak

Fatkhati Saida Rahma, Prof. Dr. dr. Agus Supartoto, Sp.M(K); dr. Firman Setya Wardhana, M.Kes, Sp.M(K); Dr. dr. Reny Setyowati, Sp.M

2026 | Tesis-Spesialis | S2 Ilmu Penyakit Mata

Latar Belakang: Katarak merupakan penyebab utama kebutaan dengan fakoemulsifikasi sebagai standar tata laksana pembedahan. Energi ultrasonik pada fakoemulsifikasi memicu stres oksidatif dan aktivasi kaskade inflamasi, yang bermanifestasi pada peningkatan kadar Monocyte Chemoattractant Protein-1 (MCP-1) serta perubahan parameter klinis okular. Profilaksis antibiotik intrakamera seperti moxifloxacin dan levofloxacin tanpa pengawet rutin diberikan untuk mencegah endoftalmitis sekaligus menekan reaktivitas radang. Penelitian ini bertujuan untuk membandingan efek injeksi intrakamera moxifloxacin tanpa pengawet dengan injeksi intrakamera levofloxacin tanpa pengawet pada kadar MCP-1 air mata serta kondisi klinis pasien katarak pascaoperasi fakoemulsifikasi.

Metode: Penelitian ini merupakan uji klinis acak terkendali dengan desain double-blind. Sebanyak 62 subjek pasien katarak (derajat LOCS III NO2-4) di RSUP Dr. Sardjito yang menjalani fakoemulsifikasi dan pemasangan lensa intraokular dialokasikan secara acak mendapat injeksi intrakamarea tanpa pengawet moxifloxacin 0,5% (n=34) dan levofloxacin 0,5% (n=28). Evaluasi mencakup kadar MCP-1 air mata (praoperasi dan H+7) yang diukur menggunakan metode ELISA, serta parameter klinis berupa Best Corrected Visual Acuity (BCVA), tekanan intraokular (TIO), derajat peradangan konjungtiva, flare dan sel, Endothelial Cell Density (ECD), Central Corneal Thickness (CCT), Coefficient of Variation (CV), dan Central Macular Thickness (CMT) yang diamati pada praoperasi, H+1, H+7, dan H+28. 

Hasil: Kadar MCP-1 sebelum operasi pada kelompok moxifloxacin sebesar 49,20 ± 13,8 pg/mL dan levofloxacin sebesar 46,95 ± 21,5 pg/mL (p=0,619). Pada hari ke-7, kadar MCP-1 masing-masing sebesar 49,15 ± 13,5 pg/mL dan 47,86 ± 18,2 pg/mL, dengan perubahan kadar yang tidak bermakna pada kedua kelompok (p=0,973 dan p=0,770). Perbandingan perubahan kadar MCP-1 antarkelompok juga tidak menunjukkan perbedaan bermakna (p=0,770). Evaluasi parameter klinis (BCVA, TIO, derajat peradangan, flare, sel, ECD, CCT, CV, dan CMT) di seluruh titik waktu pengamatan juga menunjukkan hasil yang sebanding tanpa perbedaan yang bermakna (p>0,05).

Kesimpulan: Tidak terdapat perbedaan bermakna kadar MCP-1 air mata antara pemberian injeksi intrakamera moxifloxacin tanpa pengawet dan levofloxacin tanpa pengawet setelah fakoemulsifikasi. Kedua antibiotik juga menunjukkan profil kondisi klinis yang sebanding selama 1 bulan pascaoperasi. 

Kata Kunci: moxifloxacin; levofloxacin; MCP-1; fakoemulsifikasi; inflamasi

Background: Cataract is a leading cause of blindness, with phacoemulsification being the standard surgical treatment. Ultrasonic energy during phacoemulsification induces oxidative stress and activates the inflammatory cascade, which may manifest as increased levels of Monocyte Chemoattractant Protein-1 (MCP-1) and changes in ocular clinical parameters. Intracameral antibiotic prophylaxis using preservative-free moxifloxacin and levofloxacin is routinely administered to prevent endophthalmitis while potentially reducing inflammatory reactivity. This study aimed to compare the effects of preservative-free intracameral moxifloxacin injection with preservative-free intracameral levofloxacin injection on tear MCP-1 levels and clinical conditions in cataract patients following phacoemulsification.

Methods: This was a randomized controlled clinical trial with a double-blind design. A total of 62 cataract patients (LOCS III grade NO2–4) at Dr. Sardjito General Hospital who underwent phacoemulsification and intraocular lens implantation were randomly allocated to receive preservative-free intracameral 0.5% moxifloxacin (n=34) or preservative-free intracameral 0.5% levofloxacin (n=28). Evaluations included tear MCP-1 levels, measured preoperatively and on postoperative day 7 using the ELISA method, as well as clinical parameters including Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), degree of conjunctival inflammation, flare and cells, Endothelial Cell Density (ECD), Central Corneal Thickness (CCT), Coefficient of Variation (CV), and Central Macular Thickness (CMT), assessed preoperatively and on postoperative days 1, 7, and 28.

Results: Preoperative MCP-1 levels were 49.20 ± 13.8 pg/mL in the moxifloxacin group and 46.95 ± 21.5 pg/mL in the levofloxacin group (p=0.619). On postoperative day 7, MCP-1 levels were 49.15 ± 13.5 pg/mL and 47.86 ± 18.2 pg/mL, respectively, with no significant change in either group (p=0.973 and p=0.770, respectively). The comparison of changes in MCP-1 levels between the two groups also showed no significant difference (p=0.770). Evaluation of clinical parameters (BCVA, IOP, degree of inflammation, flare, cells, ECD, CCT, CV, and CMT) at all observation time points likewise showed comparable results, with no significant differences between the groups (p>0.05).

Conclusion: There was no significant difference in tear MCP-1 levels between preservative-free intracameral moxifloxacin and preservative-free intracameral levofloxacin administration following phacoemulsification. Both antibiotics also demonstrated comparable clinical profiles during the 1-month postoperative period.

Keywords: moxifloxacin, levofloxacin, MCP-1, phacoemulsification, inflammation 

Kata Kunci : moxifloxacin, levofloxacin, MCP-1, fakoemulsifikasi, inflamasi

  1. SPESIALIS-2026-508223-abstract.pdf  
  2. SPESIALIS-2026-508223-bibliography.pdf  
  3. SPESIALIS-2026-508223-tableofcontent.pdf  
  4. SPESIALIS-2026-508223-title.pdf